A New Era in Targeted Anti-Viral Therapeutics
Imagine coursing through the blood stream, chasing through the body, grabbing and destroying the offending virus particles. NanoViricides, Inc. is striving to bring this imagination to fruition. A nanoviricide®, as defined by the Company, is a nanomachine that is armed to destroy a particular kind of virus. Which virus? That information is programmed into the nanoviricide, akin to the postal address on an envelope.
Biomimetic Technology to “Fool” Viruses
A “nanoviricide” is an agent designed by the Company to fool a virus into attaching to this antiviral nanomachine, in the same way that the virus normally attaches to the receptors on a cell surface. Once attached, the flexible nanoviricide glob wraps around the virus and traps it. In the process, the virus also loses its coat proteins that it needs to bind to a cell. The virus is thus neutralized and effectively destroyed. A nanoviricide completes the task of dismantling the virus particle without immune system assistance. This is the putative or designed mechanism of action of a nanoviricide. Thus nanoviricides represent the next great advance in “Immunotherapeutics” (antibodies and vaccines), which are currently well established antiviral strategies.
NanoViricides, Inc. is a development stage company with this unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines, that we call “nanoviricides®”.
NanoViricides, Inc. is a publicly traded company (OTC BB:Stock Symbol:NNVC)
Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. HIV, seasonal and potentially-epidemic influenzas and bird flu, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness in pre-clinical studies.
The Company has nominated a clinical candidate in its FluCide™ program.
Recent Nanoviricides Press Releases